Precision Medicine: Genetic Repair of Retinitis Pigmentosa in PatientDerived Stem Cells by Bassuk, Alexander G. et al.
1Scientific RepoRts | 6:19969 | DOI: 10.1038/srep19969
www.nature.com/scientificreports
Precision Medicine: Genetic Repair 
of Retinitis Pigmentosa in Patient-
Derived Stem Cells
Alexander G. Bassuk1, Andrew Zheng2, Yao Li2, Stephen H. Tsang2 & Vinit B. Mahajan3
Induced pluripotent stem cells (iPSCs) generated from patient fibroblasts could potentially be used 
as a source of autologous cells for transplantation in retinal disease. Patient-derived iPSCs, however, 
would still harbor disease-causing mutations. To generate healthy patient-derived cells, mutations 
might be repaired with new gene-editing technology based on the bacterial system of clustered 
regularly interspersed short palindromic repeats (CRISPR)/Cas9, thereby yielding grafts that require 
no patient immunosuppression. We tested whether CRISPR/Cas9 could be used in patient-specific 
iPSCs to precisely repair an RPGR point mutation that causes X-linked retinitis pigmentosa (XLRP). 
Fibroblasts cultured from a skin-punch biopsy of an XLRP patient were transduced to produce iPSCs 
carrying the patient’s c.3070G > T mutation. The iPSCs were transduced with CRISPR guide RNAs, Cas9 
endonuclease, and a donor homology template. Despite the gene’s repetitive and GC-rich sequences, 
13% of RPGR gene copies showed mutation correction and conversion to the wild-type allele. This is 
the first report using CRISPR to correct a pathogenic mutation in iPSCs derived from a patient with 
photoreceptor degeneration. This important proof-of-concept finding supports the development of 
personalized iPSC-based transplantation therapies for retinal disease.
Stem cell-derived cell transplantation in the eye is one therapy being explored for inherited retinal degenerations 
such as retinitis pigmentosa (RP). Recent clinical trials evaluating allogeneic retinal grafts derived from human 
embryonic stem cells (hESCs) show the procedure to be safe and potentially effective1. However, hESC-based 
treatments involve the controversial use of human embryos and pose a risk of immune-mediated rejection. Using 
a patient’s own cells for transplantation would avoid these pitfalls and is possible with induced pluripotent stem 
cells (iPSCs). Through established protocols2, fibroblasts from a skin biopsy can be returned to a pluripotent state 
and serve as a renewable, autologous source of replacement cells that avoids the ethical complications of hESCs.
Although the original disease-causing mutation would still be present in patient iPSCs, precise mutation cor-
rection is possible through gene editing techniques adapted from the bacterial clustered regularly interspersed 
short palindromic repeats (CRISPR)/Cas9 system3. The advantage of CRISPR is that its specificity depends largely 
on a guide RNA (gRNA) that can be readily programmed to target different genomic loci. In this study, we gener-
ated iPSCs from a patient with a mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene, which causes 
an aggressive, X-linked variant of RP (XLRP). We tested whether CRISPR could precisely edit the pathogenic 
mutation and produce gene-corrected iPSCs for eventual use in autologous transplantation.
Methods
All experimental protocols, including informed consent were apporved by the Institutional Review Board 
approval (AAAF1849) at Columbia University were obtained and all experiments were performed in accord-
ance with relevant approved guidelines and regulations. Informed consent was obtained for all subjects. 
Autofluorescent imaging and optical coherence tomography were performed as described4. To generate iPSCs, 
dermal fibroblasts were cultured from the skin biopsy sample and transduced according to previously described 
protocols5. Pluripotency was demonstrated by teratoma assay conducted in immunodeficient mice (Charles 
River, Wilmington, MA) and immunocytochemistry staining for pluripotency markers.
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CRISPR gRNAs were selected to minimize the off-target profile and to maximize the degree of 
homology with a target sequence directly centered on the mutation site. Candidates g58 and g59, (G58: 
GAAGTGGAAGGGGAGGTGGAAGG) and g59 (G59: AAGTGGAAGGGGAGGTGGAAGGG), were each 
Figure 1. Clinical findings and iPSCs from an adult male XLRP patient. Autofluorescence imaging of the 
patient’s [A] right and [B] left eyes shows hyperautofluorescent bull’s-eye lesions in the macula corresponding 
to [C,D] loss of photoreceptor layers (red arrows) on optical coherence tomography. [E] A skin punch biopsy 
sample (star) was taken from the patient and used to culture fibroblasts (arrowheads) that were then transfected 
with transcription factors to yield efficient formation of [F] iPSC colonies (asterisk) that stain positively for 
alkaline phosphatase. With immunocytochemistry and fluorescence microscopy, expression of pluripotency 
markers [G] SSEA4, Sox2, and [H] TRA-1-60 and OCT4 is also detected. iPSCs injected into a severe combined 
immunodeficiency (SCID) mouse formed teratomas that were found on histology to contain cell types derived 
from all three germ layers: [I,J] neuronal rosettes and pigmented cells from the ectoderm (EC), [K] smooth 
muscle cells from the mesoderm (ME), and [L] gland cells from the endoderm (EN). The expression of 
pluripotency markers in the patient-derived cells and the ability to generate differentiated cells from all three 
primordial germ layers confirms that patient iPSCs are pluripotent.
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inserted into the gRNA/Cas9 expression vector pBT-U6-Cas9-2A-GFP and transfected into a 293 cell line. 
Genomic DNA from test cells was amplified by PCR using primers for the RPGR region, and the PCR products 
were analyzed by the SURVEYOR® assay (Transgenomic, Omaha, NE) for DNA cleavage activity. The expression 
plasmid containing the g58 sequence and Cas9 were then transfected into the patient-derived C1145-11* iPSC 
line alongside a single-stranded donor oligonucleotide (ssODN) template. Ten days after transfection, cells were 
collected for PCR followed by targeted amplicon sequencing to assess for gene correction in the open reading 
frame-15 (ORF15) region containing the mutation. Deep sequencing templates were obtained by PCR of the 
genomic sequence, which also detects some non-specific PCR products (not apparent on the gel) due to the very 
high deep sequencing coverage. These non-specific sequences were categorized under “non-specific/error”. Cells 
not transfected were used as controls.
Results
We reported previously on the diagnosis of RPGR-associated XLRP in two brothers with significant vision 
loss6. Fundus examination and imaging showed a bull’s eye lesion with photoreceptor cell death near the fovea 
(Fig. 1A–D). Whole exome sequencing with Sanger sequencing confirmation uncovered a novel RPGR mutation 
(c.3070G > T, pGlu1024X) within the ORF15 exon6, a lengthy and repetitive, purine-rich region of the gene that 
accounts for > 60% of all XLRP mutations7. We then cultured fibroblasts from a skin-punch biopsy and trans-
formed them into patient-specific iPSCs. We confirmed that they were capable of differentiating into all three 
germ layers and expressed the pluripotency markers Oct-4, Sox2, SSEA-4, TRA-1-60, and alkaline phosphatase 
(Fig. 1E–L). In this state, they can be induced into retinal cells, but a critical limiting factor for transplantation is 
that they still carry a disease-causing mutation.
Next, we screened 21 gRNAs with high specificity to the region containing the patient’s RPGR mutation 
(see Supplementary Table). Two candidates were separately inserted into an expression vector also containing 
the Cas9 endonuclease responsible for mediating target DNA cleavage. A SURVEYOR® assay (Transgenomic, 
Omaha, NE) showed that one candidate, g58, had relatively high activity for the mutation site (Fig. 2). Because 
Figure 2. Validating gRNAs for gene targeting. [A] Two candidate gRNAs, g58 and g59, were selected 
based on their precise specificity for the mutation site within the ORF15 region of RPGR. [B] gRNAs were 
inserted into a combined expression vector alongside Cas9. The gRNA/Cas9 construct was transfected into 
HEK293 cells and the RPGR gene was amplified by PCR using both AccuPrime high fidelity taq polymerase 
as well as Herculase II polymerase (due to the GC-rich content of ORF15). [C] An in vitro SURVEYOR assay 
(Transgenomic, Omaha, NE) of the PCR products shows that g58 is more effective at directing cleavage by Cas9 
(bands for the expected cleavage products are indicated by red arrowheads).
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the RPGR sequence is highly repetitive, nonspecific bands were present (see methods). The calculation of cutting 
efficiency was based on the control band (before nuclease digestion) and the specific bands. The cutting efficiency 
was approximately 23% for g58. G59 was not active. Thus, g58 was used for gene editing.
Following gRNA validation, we sought to determine whether Cas9-mediated cleavage at the RPGR muta-
tion site could lead to homology-directed gene repair (HDR) in the presence of a co-transfected ssODN. We 
transfected patient iPSCs with the g58 gRNA/Cas9 expression plasmid and an RPGR anti-sense ssODN. Deep 
sequencing of transfected cells showed that 13% of reads contained precise correction of the mutation, with 
replacement of the premature stop codon “TAG” by the wild-type “GAG” codon encoding glutamate at residue 
1024 (Fig. 3). Correction of mutation was not seen in any untransfected control iPSCs.
Discussion
The goal of autologous cell replacement for retinal degenerative disease depends on the ability to correct a 
patient’s pathogenic mutation before transplantation. Here we have generated patient-specific iPSCs from an 
XLRP patient and showed that transfection of CRISPR gRNA/Cas9 alongside a donor homology template cor-
rects a point mutation within the RPGR gene ORF15 region, a challenging DNA sequence to manipulate. We 
believe this is the first report of successful gene correction in human iPSCs associated with inherited retinal 
degeneration. The present study is significant because it demonstrates that gene editing can be engineered to 
precisely target a repeat-rich region with high GC content. RPGR spans a 59,000-bp region8 in a human genome 
containing over 3 billion bases, yet 13% of sequencing reads had correction of a single nucleotide mutation within 
the repetitive, low-complexity ORF15 region, demonstrating that despite presumed technical hurdles based on 
the genomic sequence, the RPGR gene is open to CRISPR repair. This rate of repair indicates that CRISPR gene 
editing may reasonably be part of an autologous transplantation treatment for other photoreceptor degenerations 
in the future.
The alternative, and currently the more developed, therapeutic modality for genetic retinal disease is gene 
supplementation therapy. Clinical trials for RPE-associated Leber congenital amaurosis reported in 2008 that 
gene therapy9 is safe and beneficial for patients. However, recently published three-year follow-up data found 
that initial gains in retinal sensitivity waned over time and were not accompanied by meaningful improvements 
in objective measures of visual function10. Moreover, gene therapy in animal models may produce much greater 
Figure 3. Correction of RPGR mutation in patient iPSC line. [A] Dideoxy sequencing of patient DNA  
(top panel) shows the “T” point mutation (black arrow). After gRNA/Cas9 and antisense single-stranded donor 
oligonucleotide (ssODN) were transfected into the patient-derived iPSC line (bottom panel), sequencing shows 
a minor “G” peak at the same position (red arrowhead), demonstrating correction of the G > T mutation in 
a fraction of IPSC. [B,C] Deep sequencing revealed 13% of sequences in treated cells had the correct “GAG” 
codon at the position of the patient’s original “TAG” stop codon point mutation. This correction was not 
observed when untransfected control cells were sequenced.
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and more sustained rescue in humans at comparable vector doses, suggesting that interspecies genetic differences 
could limit translation to humans. These and other limits of gene therapy—such as its relative inability to treat 
dominantly inherited or late-stage disease—might be better addressed through a regenerative gene-corrected 
iPSC transplantation approach.
The 13% correction rate that we achieved is comparable to other studies of homology-directed CRISPR edit-
ing11, and exceeds previous iPSC gene editing studies reporting correction rates closer to 1%12. Such a rate can 
provide sufficient therapeutic cells, but gene-editing technology is also rapidly improving. The piggyBac transpo-
son is a mobile genetic element that can insert and excise exogenous constructs in a “footprint free” manner for 
CRISPR in iPSCs11. Minimizing error-prone non-homologous end-joining at DNA cleavage sites through inhibi-
tion of DNA ligase IV can also increase the yield of repaired cells13. Definitive analysis of off-targeting rates will be 
required before eventual clinical use. With repaired patient-specific iPSCs in hand, the next step for iPSCs trans-
plantation therapy is differentiating clonally corrected iPSCs into photoreceptors capable of integrating within the 
retina. Although a number of challenges remain, significant progress has been made in preclinical transplantation 
experiments using post-mitotic photoreceptor precursor cells or iPSC-derived en bloc retinal tissue14,15.
Conclusions
Here, we report that patient-derived iPSCs harboring a pathogenic RP mutation are amenable to precise cor-
rection by CRISPR/Cas9 gene editing. Our finding represents a concrete first step towards combining CRISPR/
Cas9-mediated gene editing with autologous iPSCs to develop a personalized transplantation strategy adaptable 
to a wide array of retinal diseases.
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